We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$51.2B
AUM Growth
+$4.14B
(+8.8%)
Cap. Flow
+$445M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
19.89%
Holding
3,234
New
648
Increased
710
Reduced
838
Closed
835
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.99B |
| 2 |
Microsoft
MSFT
|
+$522M |
| 3 |
Advanced Micro Devices
AMD
|
+$511M |
| 4 |
Amazon
AMZN
|
+$318M |
| 5 |
Apple
AAPL
|
+$317M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$402M |
| 2 |
McDonald's
MCD
|
+$375M |
| 3 |
Visa
V
|
+$366M |
| 4 |
Meta Platforms (Facebook)
META
|
+$319M |
| 5 |
Adobe
ADBE
|
+$272M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Healthcare | 17.11% |
| 3 | Consumer Discretionary | 13.31% |
| 4 | Financials | 8% |
| 5 | Industrials | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRCL
701
DELISTED
Stericycle Inc
SRCL
| $10.4M | 0.02% |
223,890
+58,170
| +35% | +$2.55M |
|
702
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$33.7B
| $10.4M | 0.02% |
96,800
+11,500
| +13% | +$1.16M |
|
703
Green Brick Partners
GRBK
$3.14B
| $10.4M | 0.02% |
+182,697
| New | +$8.5M |
|
704
Kroger
KR
$34.8B
| $10.3M | 0.02% |
+220,092
| New | +$10.5M |
|
705
Entergy
ETR
$50B
| $10.2M | 0.02% |
+210,394
| New | +$10.9M |
|
706
Target Hospitality
TH
$1.64B
| $10.2M | 0.02% |
756,524
-24,273
| -3% | -$336K |
|
707
Fair Isaac
FICO
$22.5B
| $10.1M | 0.02% |
12,495
+4,558
| +57% | +$3.42M |
|
708
TSMC
TSM
$2.18T
| $10.1M | 0.02% |
100,123
-306,956
| -75% | -$28.6M |
|
|
AVDL
709
DELISTED
Avadel Pharmaceuticals
AVDL
| $10M | 0.02% |
609,026
+301,151
| +98% | +$3.91M |
|
|
CYBR
710
DELISTED
CyberArk
CYBR
| $10M | 0.02% |
64,135
+39,888
| +165% | +$5.71M |
|
711
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $9.97M | 0.02% |
119,890
+19,770
| +20% | +$1.65M |
|
712
Ormat Technologies
ORA
$6.65B
| $9.93M | 0.02% |
123,358
-231,475
| -65% | -$19.6M |
|
713
Warby Parker
WRBY
$3.27B
| $9.9M | 0.02% |
846,980
+698,381
| +470% | +$7.95M |
|
714
Compass
COMP
$9.66B
| $9.89M | 0.02% |
2,826,077
+2,053,970
| +266% | +$6.74M |
|
|
ALE
715
DELISTED
Allete
ALE
| $9.87M | 0.02% |
+170,240
| New | +$10.5M |
|
|
716
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $9.85M | 0.02% |
118,400
-500,700
| -81% | -$41.9M |
|
717
Celldex Therapeutics
CLDX
$3.28B
| $9.82M | 0.02% |
289,523
-44,143
| -13% | -$1.49M |
|
|
718
CALL
Gilead Sciences
GILD
$165B
| $9.8M | 0.02% |
+127,200
| New | +$10.1M |
|
719
CALL
AbbVie
ABBV
$435B
| $9.79M | 0.02% |
72,700
+66,500
| +1,073% | +$9.75M |
|
720
Nomad Foods
NOMD
$1.68B
| $9.76M | 0.02% |
557,101
+64,277
| +13% | +$1.17M |
|
721
Coherus Oncology
CHRS
$196M
| $9.75M | 0.02% |
2,283,391
+1,710,463
| +299% | +$10.1M |
|
722
PUT
Morgan Stanley
MS
$340B
| $9.68M | 0.02% |
113,400
+88,100
| +348% | +$7.53M |
|
|
SCRMW
723
CALL
DELISTED
Screaming Eagle Acquisition Corp. Warrant
SCRMW
| $9.68M | 0.02% |
937,865
-101,851
| -10% | -$18.1K |
|
724
Middleby
MIDD
$6.08B
| $9.64M | 0.02% |
65,223
+38,323
| +142% | +$5.4M |
|
|
EXE
725
Expand Energy Corp
EXE
$21.5B
| $9.62M | 0.02% |
115,000
-367
| -0.3% | -$29.3K |
|
Similar funds
Marshall Wace's Q2 2023 Portfolio in Review
As of Q2 2023, Marshall Wace held 3,234 positions worth $51.2B, up 8.8% from $47.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace's Q2 2023 filing shows 648 new, 710 increased, 838 reduced and 835 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B. The largest sale was Gilead Sciences, an estimated $402M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Marshall Wace's largest Q2 2023 buy was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B.
- Marshall Wace added most to Microsoft in Q2 2023, an estimated $522M increase.
- Marshall Wace's biggest Q2 2023 reduction was Gilead Sciences, cutting an estimated $402M.
- Marshall Wace fully exited Cloudflare in Q2 2023, selling an estimated $136M.
- Marshall Wace's ten largest holdings make up 20% of its $51.2B portfolio in Q2 2023.
- Marshall Wace opened 648 new positions and closed 835 in Q2 2023.
- Marshall Wace's portfolio value rose 8.8% quarter-over-quarter to $51.2B.
Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.